Regen BioPharma Inc (RGBP)

[cvinvestor]

And the 10 Trading Day countdown to HemaX mid-Sept report news begins today! (And yes, also 1/6th of shares from convertible notes becoming free to trade began for some shares towards end of August and about 5M shares per month become free around Sept 24th, so that will also be a factor to consider with any rallies that will ensue over the coming months.)

But we are about to begin potentially the most exciting period of the past 3 years when we are not dependent on in house data, but will more and more be dependent on 3rd party experimental data based on in-house IP and research.

Recent PRs about future INDs will serve as background for new investors should the HemaX full study data give way to FDA approval to begin clinical trials, followed shortly thereafter by PR on Orphan Drug status and therefore quick development status.

If this is followed by Dr. Kesari aiding RGBP to file either a modified dCellVax IND or a new IND for glioma, Dr. Kesari's reputation and status at one of the few recognized NCRIs in the US will certainly give significantly more credence to RGBP as a viable company with valid IP than Koos ever could. And so the patterns of trading and PPS could substanitally change with just those 2 developments. Put on top of that that RGBP has announced the potential of several other INDs that could be initiated over the course of the upcoming year (remember that the Ichims incentive shares are based on 3 approved clinical trial products), and we will enter an entirely new and exciting phase for the company.

THE COUNTDOWN BEGINS!